Menu Home Search

Items which should not routinely be prescribed in primary care: A Consultation on guidance for CCGs

Updated on Monday, 6 August 2018, 843 views

Original Document

A consultation was made under the aegis of NHS Clinical Commissioners (the CCG collective body) and NHSE which closed on 21st October. Constituents might like some early warning about the drugs likely to be discouraged or even prohibited from being normally prescribed in the near future? astonishingly COPROXAMOL still costs the NHS some £9m a year and it is likely that in future all prescribing will be under a shared care agreement. DOSULEPIN is the subject of a NICE “do not do” recommendation as its tolerability in comparison with other antidepressants has been judged to be outweighed by increased cardiac risk and toxicity in overdose. DOXAZOSIN MR is judged to have no benefits compared with the relative cost of plain doxazosin. IMMEDIATE RELEASE FENTANYL in all its various forms is not to be useful enough to continue to be freely prescribed. GLUCOSAMINE & CHONDROITIN are judged to be of low clinical effectiveness as are LIDOCAINE PLASTERS. LIOTHYRONINE costs the NHS nearly £35m and is likely to be recommended only for patients undergoing treatment for thyroid cancer and to be issued by the specialist centre. LUTEIN & ANTIOXIDANTS have been the subject of two Cochrane reviews and although some with age-related macular degeneration may slow the progression of the disease there is growing evidence that taking supplements will not delay or prevent its onset. OMEGA-3 FATTY ACID COMPOUNDS are also the subject of various NICE “do not do” guidance. OXYCODONE & NALOXONE and PARACETAMOL & TRAMADOL combinations are likely to be discouraged. PERINDOPRIL ARGININE costs £6 a month compared with £1 for P. Erbutamine. RUBIFACIENTS (excluding topical NSAIDs) are also likely to be added to the list. ONCE DAILY TADALAFIL, except the specialist-prescribed version licenced for pulmonary hypertension, is judged to be clinically effective but no more so than when used “as required.” TRAVEL VACCINES including those for Hepatitis B, Japanese Encephalitis, Meningitis ACWY, Yellow fever, Tick-borne encephalitis, rabies and the BCG are still sometimes prescribed in error and cost the NHS some £4.5m a year. PHE is to conduct a review into the appropriateness of cholera, DTP, Hepatitis A and typhoid travel vaccines. TRIMIPRAMINE costs about £20m a year and more cost effective tricyclic antidepressants are available. The consultation also covers homeopathy and herbal remedies. It considers that the matter of GLUTEN-FREE products is now closed. With this in mind it is far from clear whether any of the drugs and substances listed above will actually be black-listed. We await the final decision and recommendations.

Related guidance...

Somerset LMC Weekly Update Friday 11th December 2015

Sent to all Somerset GPs and Practice Managers This and previous updates can be accessed here Functions of...

Travel Vaccine PGDs

All Somerset Practice Managers and Nurses email sent on behalf of Sue Mulvenna Dear Colleagues The new local SW Hep A PGDs are now...

Requests to convert private prescriptions to NHS FP10

Under NHS GMS Regulations the patient is entitled to receive any drug which is available on the NHS, via an NHS...

Hep B Immunisation

Hepatitis B Immunisation The following guidance is largely drawn from the BMA’s Focus on Hepatitis B Immunisations Practices may be...

Somerset LMC Weekly Update Friday 26th October 2018

Sent to all Somerset GPs and Practice Managers This and previous updates are available here Putting it all in Perspective -...

Patient Specific Directions (PSDs) and Patient Group Directions (PGDs)

The advice on the use of Patient Group Directions (PGDs) and Patient Specific Directions (PSDs) in general practice has been updated,...

Somerset LMC Weekly Update Friday 14th September 2018

All Somerset GPs and Practice Managers This and previous updates can be found here Hearts and Minds the latest blog from LMC Chairman...

What are the rules on treating overseas patients (Including Refugees and Asylum Seekers)

Do I have to treat a patient who lives overseas or is not a British citizen? Yes – anyone in England, regardless of nationality and...

GMS/PMS Contract 2018/19

Implementing the 2018/19 GP contract GMS Contract Guidance and Audit requirements 2018/19 Technical Requirements for 2018/19 GMS...

Somerset LMC Weekly Update Friday 2nd March 2018

All Somerset GPs and Practice Managers Communication, Communication, Communication the latest Blog from LMC Chairman Dr Nick Bray “Last...